# Phase II Study of Metformin for Reduction of Obesity-Associated Breast Cancer Risk

> **NCT02028221** · PHASE2 · COMPLETED · sponsor: **University of Arizona** · enrollment: 151 (actual)

## Conditions studied

- Breast Cancer Prevention

## Interventions

- **DRUG:** Metformin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02028221
- **Lead sponsor:** University of Arizona
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-03-07
- **Primary completion:** 2018-11-30
- **Final completion:** 2022-06-14
- **Target enrollment:** 151 (ACTUAL)
- **Last updated:** 2023-06-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02028221

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02028221, "Phase II Study of Metformin for Reduction of Obesity-Associated Breast Cancer Risk". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02028221. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*